Corren and colleagues have tested the monoclonal IgG2 antibody AMG 317 from Amgen (Thousand Oaks, CA, USA) binding to IL-4Rα in a phase-II clinical trial in patients with moderate to severe asthma. Here, IL4R is linked to asthma.